pediapharm Chef de file pharmaceutique en pédiatrie au Canada

Canada's Leading Pediatric Pharmaceutical Company

What's new

Pediapharm Completes Sale of Its US Rights to naproxen Suspension, Receives US$2.25 Million as First Payment of the Transaction Valued at Up to Approximately US$4.25 Million

Read more >

Pediapharm Sells its US Rights to Naproxen Suspension in a Transaction Valued at up to Approximately US$4.25 Million

Read more >

Health Canada Upholds Notice of Deficiency-Withdrawal Letter Regarding Easyhaler Budesonide

Read more >

Products

Stock – PDP.V